331 related articles for article (PubMed ID: 26177089)
21. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.
Bergua C; Torregrosa JV; Fuster D; Gutierrez-Dalmau A; Oppenheimer F; Campistol JM
Transplantation; 2008 Aug; 86(3):413-7. PubMed ID: 18698244
[TBL] [Abstract][Full Text] [Related]
22. [Changes in the pre-transplant bone-mineral metabolism do not affect the initial progress of the renal graft].
Rodrigo Calabia E; Ruiz San Millán JC; Gago M; Ruiz Criado J; Piñera Haces C; Fernández Fresnedo G; Palomar R; Gómez Alamillo C; Martín de Francisco AL; Arias M
Nefrologia; 2009; 29(2):143-9. PubMed ID: 19396320
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of a 3-Year Therapy With Cinacalcet in Persistent Hyperparathyroidism After Renal Transplant.
Rivelli GG; Lopes de Lima M; Mazzali M
Transplant Proc; 2020 Jun; 52(5):1284-1286. PubMed ID: 32204903
[TBL] [Abstract][Full Text] [Related]
24. Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients.
Sharma AK; Masterson R; Holt SG; Tan SJ; Hughes PD; Chu M; Jayadeva P; Toussaint ND
Nephrology (Carlton); 2016 Jan; 21(1):46-54. PubMed ID: 26072678
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Evaluation of Mineral Metabolism After Kidney Transplantation.
Alagoz S; Trabulus S
Transplant Proc; 2019 Sep; 51(7):2330-2333. PubMed ID: 31402243
[TBL] [Abstract][Full Text] [Related]
26. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.
Evenepoel P; Sprangers B; Lerut E; Bammens B; Claes K; Kuypers D; Meijers B; Vanrenterghem Y
Clin Transplant; 2012; 26(3):393-402. PubMed ID: 22007637
[TBL] [Abstract][Full Text] [Related]
27. Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation.
Barros X; Fuster D; Paschoalin R; Oppenheimer F; Rubello D; Perlaza P; Pons F; Torregrosa JV
Endocrine; 2015 May; 49(1):267-73. PubMed ID: 25154517
[TBL] [Abstract][Full Text] [Related]
28. The effects of mineral metabolism markers on renal transplant outcomes.
Marcén R; Jimenez S; Fernández A; Galeano C; Villafruela JJ; Burgos FJ; Quereda C
Transplant Proc; 2012 Nov; 44(9):2567-9. PubMed ID: 23146456
[TBL] [Abstract][Full Text] [Related]
29. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation.
Perrin P; Caillard S; Javier RM; Braun L; Heibel F; Borni-Duval C; Muller C; Olagne J; Moulin B
Am J Transplant; 2013 Oct; 13(10):2653-63. PubMed ID: 24034142
[TBL] [Abstract][Full Text] [Related]
30. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism.
Schwarz A; Merkel S; Leitolf H; Haller H
Transplantation; 2011 Mar; 91(5):560-5. PubMed ID: 21192318
[TBL] [Abstract][Full Text] [Related]
31. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation.
Borchhardt KA; Heinzl H; Mayerwöger E; Hörl WH; Haas M; Sunder-Plassmann G
Transplantation; 2008 Oct; 86(7):919-24. PubMed ID: 18852656
[TBL] [Abstract][Full Text] [Related]
32. Kidney Disease Improving Global Outcomes guidelines and parathyroidectomy for renal hyperparathyroidism.
Oltmann SC; Madkhali TM; Sippel RS; Chen H; Schneider DF
J Surg Res; 2015 Nov; 199(1):115-20. PubMed ID: 25982045
[TBL] [Abstract][Full Text] [Related]
33. Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients.
Barros X; Torregrosa JV; Martínez de Osaba MJ; Casals G; Paschoalin R; Durán CE; Campistol JM
Transplantation; 2012 Oct; 94(8):830-6. PubMed ID: 23018879
[TBL] [Abstract][Full Text] [Related]
34. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism.
Szwarc I; Argilés A; Garrigue V; Delmas S; Chong G; Deleuze S; Mourad G
Transplantation; 2006 Sep; 82(5):675-80. PubMed ID: 16969292
[TBL] [Abstract][Full Text] [Related]
35. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
[TBL] [Abstract][Full Text] [Related]
36. Severe hyperparathyroidism with hypercalcemia associated with chronic renal failure at pre-dialysis stage.
Takasaki I; Shionoiri H; Yabana M; Takagi N; Kamijo S; Nakatani Y; Umemura S
Endocr J; 1999 Feb; 46(1):167-71. PubMed ID: 10426582
[TBL] [Abstract][Full Text] [Related]
37. Long-term clinical practice experience with cinacalcet for treatment of hypercalcemic hyperparathyroidism after kidney transplantation.
Thiem U; Gessl A; Borchhardt K
Biomed Res Int; 2015; 2015():292654. PubMed ID: 25861621
[TBL] [Abstract][Full Text] [Related]
38. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism.
Toro Prieto FJ; Bernal Blanco G; Navarro García M; Cabello Chaves V; Garcíajiménez R; Pereira Palomo P; Gentil Govantes MA
Transplant Proc; 2009; 41(6):2144-7. PubMed ID: 19715857
[TBL] [Abstract][Full Text] [Related]
39. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
40. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
